Huntington's Disease Market Report 2026

The huntington's disease market size has grown rapidly in recent years. It will grow from $0.55 billion in 2025 to $0.64 billion in 2026 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to identification of htt gene mutation, limited availability of curative treatments, growing awareness of rare neurodegenerative diseases, reliance on symptomatic therapies, increasing diagnosis through genetic testing.

The huntington's disease market size is expected to see rapid growth in the next few years. It will grow to $1.22 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to advancements in gene therapy and rna-based treatments, rising investment in rare disease research, expanding clinical pipeline for disease-modifying therapies, growing focus on early intervention strategies, increasing support from patient advocacy organizations. Major trends in the forecast period include increasing focus on disease-modifying and gene silencing therapies, growing adoption of genetic testing for early and accurate diagnosis, rising emphasis on multidisciplinary symptom management approaches, expansion of clinical trials targeting neurodegenerative disorders, increasing patient-centric care models and home-based management.

The rising prevalence of neurological disorders is expected to drive the growth of the Huntington’s disease market in the coming years. Neurological disorders affect the brain, spinal cord, and nerves, resulting in movement, coordination, sensory, or cognitive impairments. Factors contributing to the increase in these disorders include aging populations, environmental toxins, lifestyle changes, improved diagnostic capabilities, and genetic predispositions, which facilitate the detection of more cases. Huntington’s disease is a neurodegenerative disorder caused by a genetic mutation, leading to motor dysfunction, cognitive decline, and psychiatric symptoms that progressively worsen over time. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit, reported that an estimated 6.7 million Americans aged 65 and older currently have Alzheimer’s dementia, a number projected to reach 13.8 million by 2060 without medical breakthroughs to prevent, slow, or cure the disease. Consequently, the increasing prevalence of neurological disorders is fueling the growth of the Huntington’s disease market.

Key companies in the Huntington’s disease market are focusing on innovative therapies, such as oral small molecule drugs, to treat symptoms and slow disease progression. Oral small molecule drugs are low-molecular-weight compounds that can be administered orally and interact with biological targets, such as proteins or enzymes, to treat diseases. For instance, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (USFDA) for its PTC518 program, aimed at treating Huntington’s disease. This designation highlights PTC518’s potential as a disease-modifying therapy addressing significant unmet medical needs.

In December 2024, PTC Therapeutics, Inc. partnered with Novartis AG, a Switzerland-based pharmaceutical company, to accelerate the development of PTC518 as an innovative oral treatment for Huntington’s disease. Novartis also specializes in providing branaplam (LMI070) for Huntington’s disease therapy.

Major companies operating in the huntington's disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA.

North America was the largest region in the huntington's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the huntington's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the huntington's disease market by increasing the cost of imported active pharmaceutical ingredients, advanced biologics, and specialized research equipment used in gene and cell therapy development. These impacts are most evident in disease-modifying therapy segments and in regions such as North America and Europe that depend on global biopharmaceutical supply chains. While higher costs may slow development timelines, tariffs are also encouraging local manufacturing, regional sourcing of critical inputs, and increased investment in domestic research infrastructure, supporting long-term innovation resilience.

The huntington's disease market research report is one of a series of new reports that provides huntington's disease market statistics, including huntington's disease industry global market size, regional shares, competitors with a huntington's disease market share, detailed huntington's disease market segments, market trends and opportunities, and any further data you may need to thrive in the huntington's disease industry. This huntington's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Huntington’s disease is a rare, inherited neurodegenerative disorder characterized by the progressive degeneration of nerve cells in the brain, resulting in uncontrolled movements, cognitive decline, and emotional disturbances. It is caused by a genetic mutation in the HTT gene and typically manifests in mid-adulthood.

The primary treatment types for Huntington’s disease include symptomatic therapy, disease-modifying therapy, and other treatment approaches. Symptomatic therapy aims to manage symptoms such as movement disorders, psychiatric issues, and cognitive decline without altering disease progression. Diagnosis of the disease is conducted through various methods, including magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, and other diagnostic techniques. Medications are administered via oral, parenteral, and other routes, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. These treatments are utilized by a range of end users, including hospitals, home care providers, specialty clinics, and other healthcare facilities.

The huntington's disease market consists of revenues earned by entities by providing services such as medical management, psychological and social support, and physical, occupational, and speech therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The Huntington's disease market also includes sales of tetrabenazine, deutetrabenazine, and antidepressants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.